Clinical Evaluation of Platelet Concentrates Either in Plasma or in Additive Solution

Luis Larrea*, 1, Nelly Carpio2, Cristina Arbona3, María Angeles Soler1, Javier de la Rubia 2, Roberto Roig 1
1 Centro de Transfusión de la Comunidad Valenciana, Spain
2 Hospital Universitario La Fe. Valencia, Spain
3 Hospital Clínico Universitario. Valencia, Spain

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 2
Abstract HTML Views: 2
PDF Downloads: 0
Total Views/Downloads: 4
Unique Statistics:

Full-Text HTML Views: 1
Abstract HTML Views: 2
PDF Downloads: 0
Total Views/Downloads: 3

© 2008 Larrea et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Centro de Transfusión de la Comunidad Valenciana, Avda del Cid 65, 46014 Valencia, Spain; Tel: 34963868143; Fax: 34963502469; E-mail:


Background and Objectives

Platelet concentrates (PC) obtained from Buffy-Coat (BC) may be diluted in a platelet additive solution (PAS). These PCs may reduce plasma-related adverse reactions. We have tried to assess the relationship between PAS PCs and adverse reactions.

Materials and Methods

During 6 months, patients treated with intensive chemotherapy, participated in a prospective study and were randomly assigned to receive, on a prophylactic basis, PCs in either plasma or PAS-2. Five iso-group BCs were pooled diluted in either plasma or PAS-2. One hour after each transfusion, corrected count increments (CCIs) were calculated, presence of hemorrhage and adverse reactions were recorded.


Platelet increment, 1-hour platelet count, and corrected count increments (CCI) after transfusion in both groups were similar. There were more transfusion- dependent adverse reactions in plasma group.


Use of PAS-2 resulted in less transfusion related reactions; therefore, we recommend synthetic additive solutions to dilute PCs.

Keywords: Platelet transfusions, PAS, Adverse reactions.